NCT05385744View on ClinicalTrials.gov

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

April 5, 2021

Primary Completion Date

September 9, 2022

Study Completion Date

September 29, 2023

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

BCD-132

anti-CD20 monoclonal antibody

DRUG

Teriflunomide

Teriflunomide 14 mg

Trial Locations (1)

129110

State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05385744 - An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter